Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 3/20 | 0.42 |
| ▸ | PYGM | P11217 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL7040874 | 0.91 | PPARG (0.69) | PPARGPPARANPC1CYP1A2CYP3A4 | |
| SCHEMBL7035602 | 0.90 | PPARG (0.56) | PPARGPPARAMEN1KMT2APYGL | |
| SCHEMBL7040867 | 0.82 | PPARG (0.83) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7039770 | 0.81 | PPARG (0.85) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7039776 | 0.81 | PPARG (0.85) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7155570 | 0.79 | PPARG (0.84) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7040749 | 0.78 | PPARG (0.80) | PPARGPPARASERPINE1PYGLPYGM | |
| SCHEMBL7035717 | 0.78 | PPARG (0.85) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7035715 | 0.78 | PPARG (0.85) | PPARGPPARASERPINE1MEN1KMT2A | |
| SCHEMBL7033053 | 0.78 | PPARG (0.98) | PPARGPPARASERPINE1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885SERPINE1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.